tACS: Investigational Dementia Treatment Study

Sponsor
University of Manitoba (Other)
Overall Status
Recruiting
CT.gov ID
NCT05203523
Collaborator
Riverview Health Centre Foundation (Other), Charis Senior Residences LP. DBA Aster Gardens (Other)
100
2
2
33.2
50
1.5

Study Details

Study Description

Brief Summary

This research investigates the effect of active versus sham tACS paired with cognitive exercises in a regimen protocol of weeks, everyday. The study design is a one-time crossing over design in which participants are randomized into two groups: One group will receive active treatment for 4 weeks, then 8 weeks of no treatment followed by another 4 weeks of treatment but with sham. The other group will start with sham and end up with active treatment. The study is double-blind; thus, neither participants, nor the assessors know the group assignment.

The Intervention is applying tACS either active or sham paired with cognitive exercises (MindTriggers app games).

Note: The above study will run at both University of Manitoba (U of M) and Aster Gardens residence. However, at Aster Gardens Residence only questionnaire type of assessments will be run, while in U of M, the investigators will have three other major assessments as well. In addition, the investigators will run the assessments at the Aster Gardens Residence through online sessions.

Condition or Disease Intervention/Treatment Phase
  • Device: transcranial alternative current stimulation (tACS)
  • Other: cognitive exercises
N/A

Detailed Description

This research will investigate the effect of applying transcranial alternating current stimulation (tACS) when paired with cognitive exercises on older adults in a placebo-controlled double-blind study with statistical rigor. In addition, the investigators will investigate and explore novel technological methods not only to monitor the plausible changes due to intervention but also to predict the response of a participant to the intervention at baseline. Since most technological intervention on dementia have a demanding and costly protocol, it would be of great interest to have a reliable prediction of a participant to a treatment at baseline; that would lead to personalized optimum treatment strategy. The investigators will use Electrovestibulography (EVestG), Egocentric Spatial Assessment using our Virtual Reality Navigation (VRN) and functional near infrared spectroscopy (fNIRS) measurements and analysis to develop the monitoring and predicting technologies. EVestG is a non-invasive measure of the vestibuloacoustic system in both background (no motion) and in response to passive whole-body tilt stimuli. The investigators hypothesize there is a direct link between vestibular system deficiencies and Alzheimer's. VRN measures how people orient themselves in a non-familiar environment; the investigators hypothesize it is deteriorated significantly in Alzheimer's even at its onset. fNIRS measures oxygenated and deoxygenated blood flow to the brain and it may help to understand neuronal changes due to intervention.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
This human research study is a crossover, placebo controlled and double-blind study. It will have two groups of subjects matched in age, and sex and cognitive level (measured by Montreal Cognitive Assessment: MoCA). Group 1 (G1) participants will receive active tACS simultaneously with cognitive exercises. Group 2 (G2) participants will receive sham tACS simultaneously with cognitive exercises. The volunteers who cannot tolerate application of tACS and focus on the cognitive exercises at the same time, will be enrolled in a third group (G3); they will receive only cognitive exercises with the same protocol as in G1 and G2. We will use only two periods design (one time crossing over).This human research study is a crossover, placebo controlled and double-blind study. It will have two groups of subjects matched in age, and sex and cognitive level (measured by Montreal Cognitive Assessment: MoCA). Group 1 (G1) participants will receive active tACS simultaneously with cognitive exercises. Group 2 (G2) participants will receive sham tACS simultaneously with cognitive exercises. The volunteers who cannot tolerate application of tACS and focus on the cognitive exercises at the same time, will be enrolled in a third group (G3); they will receive only cognitive exercises with the same protocol as in G1 and G2. We will use only two periods design (one time crossing over).
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description:
The group assignment is known only by the study coordinator and the PI. Group assignment will be randomized into either Group 1 or Group 2 using PROC PLAN procedure of SAS randomization. The group assignment of a participant could potentially be unblinded on compassionate ground (e.g., if a participant comes from a different city for the duration of the study) or request of the participant or any emergency situation (although very rare). In that case the participant's data may be excluded from the analysis totally or depending on when this unblinding occur, half of the data might be usable for analysis (if unblinding occur during the waiting period before crossing over). The unblinding decision will be made by the PI.
Primary Purpose:
Treatment
Official Title:
Investigating the Effect of Cognitive Training With and Without Transcranial Alternating Current Stimulation on the Executive Brain Functions in Dementia Population
Actual Study Start Date :
Jan 24, 2022
Anticipated Primary Completion Date :
Nov 1, 2024
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group 1 (G1)

Participants will receive active tACS simultaneously with cognitive exercises.

Device: transcranial alternative current stimulation (tACS)
A light electrical current will be applied to the scalp of the participants via 2 electrodes, while the participants performs cognitive exercises with the guidance of a trained research assistant.

Other: cognitive exercises
Participant will perform memory and learning games/tasks through "Mind Triggers" app on an IPad. Participants will be guided by a highly trained research assistant.

Sham Comparator: Group 2 (G2)

Participants will receive sham tACS simultaneously with cognitive exercises.

Other: cognitive exercises
Participant will perform memory and learning games/tasks through "Mind Triggers" app on an IPad. Participants will be guided by a highly trained research assistant.

Outcome Measures

Primary Outcome Measures

  1. Change from baseline Wechsler Memory Scale (WMS-IV) Older Adult Battery Score at five, eleven and sixteen weeks. [Baseline (week 0), week 5, week 11, week 16]

    Cognitive and memory task that focus on 6 major memory indexes: Auditory Memory, Visual Memory, Visual Working Memory, Immediate Memory, Delayed Memory, and Recognition Memory.

Secondary Outcome Measures

  1. N-back test [Baseline (week 0), week 5, week 11, week 16]

    N is a number between 1 and 4. A sequence of random shapes is presented and the participant has to tap or say if (remember) whether a presented object is a repeat of the Nth previous object. We will use this test with N=1 as for N>1 is very challenging for dementia population to perform.

  2. Neuropsychiatric Inventory Questionnaire (NPIQ) [Baseline (week 0), week 5, week 11, week 16]

    Questionnaire used to assesses neuropsychiatric symptoms and caregiver burden The score of the NPIQ is based on the presence of a specified symptom and a separate score for severity of the symptom. For presence the minimum total score is 0, maximum score is 12. For severity the minimum total score is 0, maximum is 36. Higher scores indicate the participant is exhibiting more severe changes in behaviors.

  3. Functional Near Infrared Spectroscopy (fNIRS) [Baseline (week 0), week 5, week 11, week 16]

    fNIRS is a device designed mainly for measuring the blood flow over the prefrontal cortex. Participants will perform a verbal fluency task while the fNIRS measures signals simultaneously.

  4. Electrovestibulography (EVestG) [Baseline (week 0), week 5, week 11, week 16]

    EVestG is explored as a monitoring and predictive tool for treatment efficacy, starting at baseline. If participant's ears are free of wax, blood, scarring, then they will be eligible for electrode placement and EVestG recording.

  5. Virtual Reality Navigation (VRN) spatial orientation test [Baseline (week 0), week 5, week 11, week 16]

    The VRN test will be run in non-immersive mode using a large screen and joystick in the PI's office at Riverview Health Center by one of the VRN team member (a research assistant). This program runs only on PC. Run the "rummeego.bat" file in the folder VRN V5 to run the program. Press "s" button to rotate the building. Pressing "Esc" exits that trial and goes to next. The VRN has two stages: 1) Localization, 2) Navigation. The second stage will be carried out only if a participant can pass the localization stage with a score >15 (basically with no consistent side error).

  6. Speech analysis [Baseline (week 0), week 5, week 11, week 16]

    During WMS-IV assessment, participants are interviewed with a chit-chat about their daily life and events. For speech assessment, we use the first few minutes of that interview as well as the spoken parts of the WMS-IV assessment, where the participant has to recall a story, will be recorded and used. This assessment is basically signal (speech) processing of the recorded audio at each assessment time and find features that could be representative of a change due to treatment.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 95 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • ability to read, write and speak English fluently
Exclusion Criteria:
  • Being diagnosed with Parkinson's, Parkinsonian dementia, Huntington disease, speech significant aphasia and intellectual disability, major depression/anxiety, bipolar disorder, schizophrenia or any other major mood disorder

  • Having a History of epileptic seizures or epilepsy

  • Inability to adequately communicate in English

  • Impaired vision or hearing severe enough to impair performance in cognitive tests

  • Current substance abuse disorder

  • Currently participating in another therapeutic study for dementia

  • Plan to change the medication during this study's period

Contacts and Locations

Locations

Site City State Country Postal Code
1 Aster Gardens Edmonton Alberta Canada
2 Riverview Health Centre Winnipeg Manitoba Canada R3L 2P4

Sponsors and Collaborators

  • University of Manitoba
  • Riverview Health Centre Foundation
  • Charis Senior Residences LP. DBA Aster Gardens

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr. Zahra Kazem-Moussavi, Professor, Dept. of Electrical and Computer Eng. Director Biomedical Engineering, University of Manitoba
ClinicalTrials.gov Identifier:
NCT05203523
Other Study ID Numbers:
  • HS25171(B2021:089)
First Posted:
Jan 24, 2022
Last Update Posted:
Mar 2, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 2, 2022